media – Page 10 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Semaglutide sold for $20.3 billion!

On November 6, Novo Nordisk released its third-quarter report for 2024. In the first nine months of this year, sales increased by 23% to 204.7 billion Danish kroner, of which sales of diabetes and obesity treatment drugs increased by 25% to 191.8 billion Danish kroner. The star product Semaglutide continued to advance by leaps and bounds, with sales of three brands (sugar-lowering injection Ozempic, sugar-lowering tablets Rybelsus, and weight-loss injection Wegovy) reaching 141.213 billion Danish kroner, or about 20.3 billion US dollars, in the first nine months of this year. Not long ago, Eli Lilly also announced its performance, among which the sales of two brands of GIPR/GLP-1R dual agonist Tirzepatide (Mounjaro, a hypoglycemic injection, and Zepbound, a weight loss injection) reached US$11.0284 billion in the first three quarters of this year. Specifically, Mounjaro’s sales revenue was US$8.010 billion, and Zepbound’s sales revenue was US$3.018 billion. Zepbound has been rapidly ...
- Source: drugdu
- 61
- November 9, 2024
New eye medicine company will lay tens of billions of “golden eggs”

In front of the old domestic eye medicine leaders such as Yisheng Bio and Xingqi Eye Medicine, Zhaoke Ophthalmology is a young upstart. In 2021, Zhaoke Ophthalmology successfully landed on the Hong Kong Stock Exchange as the second eye medicine biotechnology company with 25 ophthalmic drug candidates. Three years later, although it has not yet gotten out of the quagmire of losses, Zhaoke Ophthalmology is still working hard in the eye medicine track and finally ushered in the opportunity to overtake on the curve. Two years of rapid growth, fierce attack on the “first billion drug” Recently, Zhaoke Ophthalmology announced that the Phase III clinical trial (China CHAMP) of its eye medicine candidate NVK002 has achieved positive top-line results. NVK002 is an experimental new topical ocular solution for controlling the deepening of myopia in children and adolescents (using 0.01% and 0.02% low-dose atropine). This is the most popular atropine myopia ...
- Source: drugdu
- 71
- November 9, 2024
Global New Drug Progress and New Sharing

Progress in drug research and development 1. Anjin C5aR antagonist “Avamipram” approved for market in China On November 5th, the official website of NMPA announced that the marketing application for avacopan capsules jointly developed by Anjin and CSL Vifor has been approved, presumably for the treatment of anti neutrophil cytoplasmic antibody (ANCA) – related vasculitis (AAV). Afakepan is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the allergen C5a, blocking C5a mediated neutrophil activation and migration. The drug was approved by the US FDA in October 2021 for use in combination with standard treatment regimens including glucocorticoids to treat adult active severe ANCA associated vasculitis (MPA and GPA). In July 2024, Anjin reached an agreement with CSL Vifor to acquire commercial rights to Avamipram in Asia and Latin America, including the mainland Chinese market. 2. Pfizer PARP inhibitor “Terazopanib” approved in China On November 5th, ...
- Source: drugdu
- 72
- November 8, 2024
Gan & Lee aims at the hypoglycemic drug market

Collective procurement ‘big winner’ In 1995, Gan Zhongru, who had worked as a postdoctoral fellow and senior biochemist at Merck&Co. in the United States, returned to China to start a business. Three years later, the team formed by Gan Zhongru developed China’s first genetically recombinant human insulin, becoming the third company after Eli Lilly and Novo Nordisk to produce and sell recombinant human insulin. Subsequently, under the leadership of Gan Zhongru and his R&D team, Gan Li Pharmaceutical continued to develop the first long-acting insulin analog, the first fast acting insulin analog, the first pre mixed insulin analog, and the first winter insulin in China. The products covered three insulin functional segments: long-acting, fast acting, and medium acting, becoming the “king of insulin” in China. With the acceleration of domestic insulin substitution in recent years, Ganli Pharmaceutical’s operating revenue has increased from 1.771 billion yuan in 2016 to 3.612 billion ...
- Source: drugdu
- 75
- November 8, 2024
Let’s look at the suspense of the King of Medicine

On October 31, Merck was the first to release its third-quarter financial report. In the first three quarters, K drug performed as well as ever, with sales of US$21.646 billion, a year-on-year increase of 18%, and annual sales are expected to exceed US$29 billion. According to this trend, K drug is likely to defend the title of King of Medicine in 2024. However, on November 6, after Novo Nordisk released its third-quarter report, the competition for the King of Medicine caused a stir. In the first three quarters, the total sales of multiple versions of semaglutide reached US$20.3 billion, approaching K drug. Such a limited gap also indicates the fierceness of the competition for the King of Medicine. Before the results of the fourth quarter are announced, no one knows the final answer. Will K drug become the “shortest-lived King of Medicine” in history? On February 1, 2024, with the ...
- Source: drugdu
- 57
- November 8, 2024
【EXPERT Q&A】IVD self-test products apply for EU CE, need to pay attention to what?

Drugdu.com expert’s response: When applying for the CE certification for IVD self-test products in the EU, attention should be paid to the following aspects: Ⅰ. Understanding the IVDR Regulatory Requirements Regulatory Content: IVD self-test products need to comply with the regulations of the In Vitro Diagnostic Medical Devices Regulation (IVDR, Regulation (EU) 2017/746). Product Classification: According to the IVDR, IVD products are classified into four risk categories: A, B, C, and D. Self-test products, which typically involve patients performing their own tests, may fall into higher risk categories, requiring special attention to relevant audit requirements. Ⅱ. Preparing Technical Documentation Completeness: Technical documentation should include product instructions, technical specifications, validation reports, quality control manuals, etc., and should be organized and numbered according to the order specified in Appendix II of the IVDR. Accuracy: The content of the documentation should be accurate and reflect the true performance and safety of the product. ...
- Source: drugdu
- 62
- November 8, 2024
PCR new legend debuts at CIIE! Roche Diagnostics releases LightCycler® PRO

Today, at the 7th China International Import Expo (hereinafter referred to as “CIIE”), Roche Diagnostics China announced that its new molecular detection platform LightCycler® PRO System real-time fluorescence quantitative PCR instrument* (hereinafter referred to as “LightCycler® PRO”) was officially launched in China. Wang Feng, Senior Director of Roche Diagnostics China – Life Sciences Department, Marcus Droege, CEO of TIB Molbiol, James Lee, Global Senior Product Manager of Roche Diagnostics, and other guests attended the LightCycler® PRO launch conference. “As a global leader in in vitro diagnostics, Roche Diagnostics has always empowered scientific research with cutting-edge innovative technologies and led the development of the industry. LightCycler® PRO is another breakthrough innovation in the field of molecular testing. It can achieve 7-channel multiplex testing and has powerful advantages such as accuracy, high efficiency, flexibility, and ease of use. We hope that this time, with the help of the CIIE, it will officially ...
- Source: drugdu
- 56
- November 8, 2024
Haichen Pharmaceutical Approved for Additional Injection Specification of Labetalol Hydrochloride 150mg

On November 6, Haichen Pharmaceutical (300584) announced that it has received approval for the addition of a new specification for injection of Labetalol Hydrochloride 150mg through a supplemental drug application. The company recently received a notification from the National Medical Products Administration, approving the addition of the 150mg specification based on the already approved 50mg specification, and is considered to have passed the consistency evaluation. The registration classification of this approval is for chemical drugs, with the manufacturing enterprise being the company itself. The approval number is H20247263. The addition of the new specification will involve changes to the production process, which must be implemented within six months from the date of approval. Labetalol Hydrochloride injection is a novel ultra-short-acting beta-blocker, clinically suitable for the emergency treatment of various rapid cardiac arrhythmias. In 2023, this product generated sales revenue of 267 million yuan, accounting for 51.59% of the company’s total ...
- Source: drugdu
- 45
- November 8, 2024
The world’s first, created in China! Weekly insulin preparation Novozyme® debuts at CIIE, to be launched at the end of the month

On November 6, at the 7th China International Import Expo (hereinafter referred to as “CIIE”), Novo Nordisk held a press conference and announced that the world’s first weekly insulin formulation, Novozymes® (insulin Efficacy Injection), which was exhibited for the first time at this CIIE, will be commercially launched in China at the end of November 2024 for the treatment of type 2 diabetes in adults, ushering in the era of weekly insulin treatment. Professor Peng Yongde, head of the Department of Endocrinology and Metabolism at the First People’s Hospital affiliated to Shanghai Jiao Tong University School of Medicine, said: “Insulin therapy is still an indispensable and important cornerstone in the diabetes management pathway. As a key component, basal insulin strives to better meet clinical treatment needs to help patients start treatment in a timely manner, improve treatment compliance, increase treatment continuity, and improve patient satisfaction.” Insulin “from day to week” ...
- Source: drugdu
- 58
- November 8, 2024
Cell Drug Conjugates – An Innovative Drug Delivery System

In recent years, cell drug conjugates (CDCs) have gradually become a hot topic in medical research as an emerging drug delivery system. On July 1, 2024, Professor Gu Zhen and others from Zhejiang University published a review paper titled “Cell Drug Conjugates” in the Nature Journal of Biomedical Engineering. The article deeply explores the principles, preparation methods, and applications of this technology in cancer and immune diseases. This article will explain the content of the literature in detail, taking you to understand the core and prospects of this innovative technology. 01 What are cell drug conjugates (CDCs)? Cell drug conjugates are a complex that combines live cells and therapeutic drugs, capable of simultaneously exerting the functions of both, particularly suitable for the treatment of complex diseases such as cancer and autoimmune disorders. Unlike traditional drug delivery systems such as liposomes, nanoparticles, etc., CDCs utilize the physiological characteristics of cells, ...
- Source: drugdu
- 56
- November 7, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.